PortfoliosLab logoPortfoliosLab logo
Biomerica, Inc. (BMRA)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US09061H3075
CUSIP
09061H307
IPO Date
Jan 3, 2005

Highlights

Market Cap
$6.17M
Enterprise Value
$4.19M
EPS (TTM)
-$0.79
Total Revenue (TTM)
$4.46M
Gross Profit (TTM)
$250.00K
EBITDA (TTM)
-$3.68M
Year Range
$1.87 - $4.88
ROA (TTM)
-66.71%
ROE (TTM)
-90.76%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Biomerica, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Biomerica, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Biomerica, Inc. (BMRA) has returned -15.87% so far this year and -53.26% over the past 12 months. Over the last ten years, BMRA has returned -13.88% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Biomerica, Inc.

1D
3.41%
1M
1.92%
YTD
-15.87%
6M
-25.09%
1Y
-53.26%
3Y*
-47.86%
5Y*
-46.23%
10Y*
-13.88%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jan 3, 2005, BMRA's average daily return is +0.20%, while the average monthly return is +1.37%. At this rate, your investment would double in approximately 4.2 years.

Historically, 46% of months were positive and 54% were negative. The best month was Mar 2020 with a return of +155.4%, while the worst month was Dec 2018 at -39.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.

On a daily basis, BMRA closed higher 35% of trading days. The best single day was Mar 18, 2020 with a return of +334.6%, while the worst single day was Mar 20, 2020 at -55.3%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-5.75%-12.42%1.92%-15.87%
202568.24%45.55%-22.85%-20.19%-15.75%3.61%2.53%-3.40%-9.58%-1.41%-15.05%6.33%4.97%
2024-25.60%31.18%-31.80%-28.37%-2.58%-24.25%-24.76%32.97%-25.55%13.55%4.84%-23.05%-75.99%
2023-10.45%-10.00%-30.74%-28.88%3.01%-0.73%-2.94%-3.03%-32.80%13.93%-5.10%34.41%-62.69%
20229.51%1.88%3.00%-12.08%-10.94%-17.43%-4.15%27.80%11.02%-16.28%5.78%-3.74%-13.88%
202136.55%-9.85%-10.93%-14.65%-21.67%9.86%-6.48%19.47%0.45%2.00%5.66%-19.79%-21.89%

Benchmark Metrics

Biomerica, Inc. has an annualized alpha of 62.16%, beta of 0.22, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 04, 2005.

  • This stock participated in 46.33% of S&P 500 Index downside but only 16.45% of its upside — more exposed to losses than it benefited from rallies.
  • Beta of 0.22 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
62.16%
Beta
0.22
0.00
Upside Capture
16.45%
Downside Capture
46.33%

Return for Risk

Risk / Return Rank

BMRA ranks 9 for risk / return — in the bottom 9% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


BMRA Risk / Return Rank: 99
Overall Rank
BMRA Sharpe Ratio Rank: 99
Sharpe Ratio Rank
BMRA Sortino Ratio Rank: 1010
Sortino Ratio Rank
BMRA Omega Ratio Rank: 1111
Omega Ratio Rank
BMRA Calmar Ratio Rank: 55
Calmar Ratio Rank
BMRA Martin Ratio Rank: 1111
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Biomerica, Inc. (BMRA) and compare them to a chosen benchmark (S&P 500 Index).


BMRABenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.77

0.90

-1.66

Sortino ratio

Return per unit of downside risk

-1.04

1.39

-2.42

Omega ratio

Gain probability vs. loss probability

0.87

1.21

-0.34

Calmar ratio

Return relative to maximum drawdown

-0.94

1.40

-2.34

Martin ratio

Return relative to average drawdown

-1.42

6.61

-8.03

Explore BMRA risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Biomerica, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Biomerica, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biomerica, Inc. was 98.50%, occurring on Mar 6, 2026. The portfolio has not yet recovered.

The current Biomerica, Inc. drawdown is 98.34%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.5%Mar 20, 20201498Mar 6, 2026
-80.56%Oct 4, 2007837Jan 28, 20111340May 26, 20162177
-67.92%Jan 11, 2018244Dec 31, 2018305Mar 18, 2020549
-49.33%Jun 14, 2005399Jan 12, 200763Apr 16, 2007462
-45.99%Aug 23, 201655Nov 8, 2016249Nov 3, 2017304

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biomerica, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Biomerica, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BMRA relative to other companies in the Medical Devices industry. Currently, BMRA has a P/S ratio of 2.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BMRA in comparison with other companies in the Medical Devices industry. Currently, BMRA has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items